Cargando…

The impact of immuno-aging on SARS-CoV-2 vaccine development

The SARS-CoV-2 pandemic has almost 56 million confirmed cases resulting in over 1.3 million deaths as of November 2020. This infection has proved more deadly to older adults (those >65 years of age) and those with immunocompromising conditions. The worldwide population aged 65 years and older is...

Descripción completa

Detalles Bibliográficos
Autores principales: Connors, Jennifer, Bell, Matthew R., Marcy, Jennifer, Kutzler, Michele, Haddad, Elias K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875765/
https://www.ncbi.nlm.nih.gov/pubmed/33569701
http://dx.doi.org/10.1007/s11357-021-00323-3
_version_ 1783649829578080256
author Connors, Jennifer
Bell, Matthew R.
Marcy, Jennifer
Kutzler, Michele
Haddad, Elias K.
author_facet Connors, Jennifer
Bell, Matthew R.
Marcy, Jennifer
Kutzler, Michele
Haddad, Elias K.
author_sort Connors, Jennifer
collection PubMed
description The SARS-CoV-2 pandemic has almost 56 million confirmed cases resulting in over 1.3 million deaths as of November 2020. This infection has proved more deadly to older adults (those >65 years of age) and those with immunocompromising conditions. The worldwide population aged 65 years and older is increasing, and the total number of aged individuals will outnumber those younger than 65 years by the year 2050. Aging is associated with a decline in immune function and chronic activation of inflammation that contributes to enhanced viral susceptibility and reduced responses to vaccination. Here we briefly review the pathogenicity of the virus, epidemiology and clinical response, and the underlying mechanisms of human aging in improving vaccination. We review current methods to improve vaccination in the older adults using novel vaccine platforms and adjuvant systems. We conclude by summarizing the existing clinical trials for a SARS-CoV-2 vaccine and discussing how to address the unique challenges for vaccine development presented with an aging immune system.
format Online
Article
Text
id pubmed-7875765
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-78757652021-02-11 The impact of immuno-aging on SARS-CoV-2 vaccine development Connors, Jennifer Bell, Matthew R. Marcy, Jennifer Kutzler, Michele Haddad, Elias K. GeroScience Original Article The SARS-CoV-2 pandemic has almost 56 million confirmed cases resulting in over 1.3 million deaths as of November 2020. This infection has proved more deadly to older adults (those >65 years of age) and those with immunocompromising conditions. The worldwide population aged 65 years and older is increasing, and the total number of aged individuals will outnumber those younger than 65 years by the year 2050. Aging is associated with a decline in immune function and chronic activation of inflammation that contributes to enhanced viral susceptibility and reduced responses to vaccination. Here we briefly review the pathogenicity of the virus, epidemiology and clinical response, and the underlying mechanisms of human aging in improving vaccination. We review current methods to improve vaccination in the older adults using novel vaccine platforms and adjuvant systems. We conclude by summarizing the existing clinical trials for a SARS-CoV-2 vaccine and discussing how to address the unique challenges for vaccine development presented with an aging immune system. Springer International Publishing 2021-02-11 /pmc/articles/PMC7875765/ /pubmed/33569701 http://dx.doi.org/10.1007/s11357-021-00323-3 Text en © American Aging Association 2021
spellingShingle Original Article
Connors, Jennifer
Bell, Matthew R.
Marcy, Jennifer
Kutzler, Michele
Haddad, Elias K.
The impact of immuno-aging on SARS-CoV-2 vaccine development
title The impact of immuno-aging on SARS-CoV-2 vaccine development
title_full The impact of immuno-aging on SARS-CoV-2 vaccine development
title_fullStr The impact of immuno-aging on SARS-CoV-2 vaccine development
title_full_unstemmed The impact of immuno-aging on SARS-CoV-2 vaccine development
title_short The impact of immuno-aging on SARS-CoV-2 vaccine development
title_sort impact of immuno-aging on sars-cov-2 vaccine development
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7875765/
https://www.ncbi.nlm.nih.gov/pubmed/33569701
http://dx.doi.org/10.1007/s11357-021-00323-3
work_keys_str_mv AT connorsjennifer theimpactofimmunoagingonsarscov2vaccinedevelopment
AT bellmatthewr theimpactofimmunoagingonsarscov2vaccinedevelopment
AT marcyjennifer theimpactofimmunoagingonsarscov2vaccinedevelopment
AT kutzlermichele theimpactofimmunoagingonsarscov2vaccinedevelopment
AT haddadeliask theimpactofimmunoagingonsarscov2vaccinedevelopment
AT connorsjennifer impactofimmunoagingonsarscov2vaccinedevelopment
AT bellmatthewr impactofimmunoagingonsarscov2vaccinedevelopment
AT marcyjennifer impactofimmunoagingonsarscov2vaccinedevelopment
AT kutzlermichele impactofimmunoagingonsarscov2vaccinedevelopment
AT haddadeliask impactofimmunoagingonsarscov2vaccinedevelopment